AccessDX Holdings, a provider of advanced laboratory diagnostic solutions, has acquired 2Israeli medtech firm 2bPrecise from Allscripts Healthcare Solutions. The purchase price was not disclosed.
The 2bPrecise platform, states the company, consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. It brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are equipped to drive efficient workflows for genomic workflows and decision-making, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more
One area in which 2bPrecise works is called Pharmacogenomics. The CDC explains that Pharmacogenomics is an example of the field of precision medicine, which aims to tailor medical treatment to each person or to a group of people. Pharmacogenomics looks at how your DNA affects the way you respond to drugs. In some cases, your DNA can affect whether you have a bad reaction to a drug or whether a drug helps you or has no effect.
The CDC says that Pharmacogenomics can improve your health by helping you know ahead of time whether a drug is likely to benefit you and be safe for you to take. Knowing this information can help your doctor find medicine that will work best for you.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
2bPrecise also works with precision oncology. The Mayo clinic explains that cancers develop and respond to therapies differently from one patient to the next. A better understanding of the specific processes driving cancer growth and spread in an individual patient allows for tailored therapeutic strategies that are more effective with minimal side effects. Profiling the mutations and abnormalities that drive a tumor, in combination with development of experimental models that assess the specific responses of cancer cells to therapeutics that target those abnormalities, has dramatically improved outcomes in many cancer types.
Big news! 2bPrecise has been acquired by @accessdxlab! Together, we’ll create the industry’s most advanced #precisionmedicine enablement solution. Read the release here: https://t.co/7jbUFeWogH pic.twitter.com/j88y0f3xlj
— 2bPrecise (@2bPrecise) August 27, 2021
“AccessDX is a genuine leader in genomic information management. Our collective capabilities will serve as a force multiple for the practical utilization of precision medicine,” said Assaf Halevy, founder and CEO of 2bPrecise. “With a unified mission to drive dimensional change in healthcare, the combined talents and energy of 2bPrecise and AccessDX will compound acceleration in delivering on our vision of intelligent, personalized care for the good of healthcare organizations and the patients they serve.”